To hear about similar clinical trials, please enter your email below
Trial Title:
Comparsion Between Intravenous Infusion of Ketofol and Inhalational Anasthetics in Abdominal Cancer Surgeries for Post Operative Analgesia
NCT ID:
NCT06265948
Condition:
Abdominal Cancer
Conditions: Official terms:
Abdominal Neoplasms
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Summary:
( post operative pain between intravenous infusion ketofol and standard inhalational
general anesthesia in abdominal cancer surgeries )
Detailed description:
ketofol, which is a combination of ketamine and propofol, has been increasingly used
because the advantages and disadvantages of propofol and ketamine complement each other
and increase their effectiveness. Recently, the use of a combination of ketamine and
propofol (ketofol) as a sedative has been attracting attention in various clinical
fields. Theoretically, the combination of ketamine and propofol can reduce the dose of
each drug and compensate for the disadvantages of the other through the antagonistic
characteristics of both drugs, resulting in beneficial results for successful sedation
. Most of the time propofol and ketamine have been used as an induction agent in adult
surgical patients but propofol may cause cardiorespiratory depression while ketamine
increases heart rate and arterial blood pressure. On the other hand, the clinical effects
of propofol and ketamine seem to be complementary. Ketofol is most commonly used for
procedural sedation hence exploring its effectiveness for induction will be paramount for
the clinical care of surgical patients Inhalation anesthetics (nitrous oxide, halothane,
isoflurane, desflurane, sevoflurane, most commonly used agents in practice today) are
used for induction and maintenance of general anesthesia in the operating room. The
volatile anesthetics (halothane, isoflurane, desflurane, and sevoflurane) are liquids at
room temperature and require the use of vaporizers for inhalational administration.
Nitrous Oxide is already under normal conditions of temperature and pressure. All
inhalational anesthetics provide amnesia and immobility, except for nitrous oxide, which
also provides analgesia. Inhaled anesthetics are commonly used in combination with IV
anesthetic agents. These agents have FDA approval for use as a general anesthetic and
sedation agent in the operating room. Inhaled anesthetic agents have also had use in the
intensive care unit, but this is not an FDA-approved indication. The primary applications
of inhaled anesthetic agents in the ICU are sedation, refractory bronchospasm, and
control of status epilepticus unresponsive to anticonvulsant medications.
Criteria for eligibility:
Study pop:
Inclusion Criteria:
- a. Inclusion criteria:
1. Age group 18 - 60 years old.
2. Both gender
3. ASA 1and 2
Exclusion Criteria:
- a. Inclusion criteria:
1. Age group 18 - 60 years old.
2. Both gender
3. ASA 1and 2 b. Exclusion criteria:
1. Patient refusal,
2. History of cardiac or respiratory disease, psychological disorders,
3. High risk of regurgitation or aspiration based on a history of diabetes,
hiatus hernia, gastroesophageal reflux, and obesity,
4. neck pathology,
5. Predicted difficult airway (history of difficult airway, mouth opening
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- a. Inclusion criteria:
1. Age group 18 - 60 years old.
2. Both gender
3. ASA 1and 2
Exclusion Criteria:
- a. Inclusion criteria:
1. Age group 18 - 60 years old.
2. Both gender
3. ASA 1and 2 b. Exclusion criteria:
1. Patient refusal,
2. History of cardiac or respiratory disease, psychological disorders,
3. High risk of regurgitation or aspiration based on a history of diabetes,
hiatus hernia, gastroesophageal reflux, and obesity,
4. neck pathology,
5. Predicted difficult airway (history of difficult airway, mouth opening
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Start date:
March 2024
Completion date:
May 2025
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06265948
